4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development. Oncothyreon Inc. (USA) (NASDAQ:ONTY) stock performance was 1.92% in last session and finished the day at $3.72. Traded volume was 1.16 million shares in the last session and the average volume of the stock remained 904,463.00 shares. The beta of the stock remained 2.10. Oncothyreon Inc. (USA) (NASDAQ:ONTY) insider ownership is 0.10%.
IGI Laboratories, Inc. (NYSEMKT:IG), a New Jersey based generic topical pharmaceutical company, yesterday announced it has received its first approval from the U.S. IGI Laboratories, Inc. (NYSEMKT:IG) rose 1.29% to $4.71 yesterday on volume of 679,515.00 shares. The intra-day range of the stock was $4.49 – $5.00. IGI Laboratories, Inc. (NYSEMKT:IG) has a market capitalization of 204.40 million.
TG Therapeutics, Inc. (NASDAQ:TGTX) announce Tuesday that it was selling about 2.7 million share of its common stock to an intuitional investor. Each share in this underwritten sale will be sold at $6.71 which reflects the closing price on Monday. The stock will be sold to Global Healthcare Fund which is a business owned by JP Morgan Asset Management. Approximately $18.1 million is expected to be raised from the transaction. TG Therapeutics, Inc. (NASDAQ:TGTX)’s stock on March 12, 2014 reported a higher of 10.28% to the closing price of $7.40. Its fifty two weeks range is $2.97 – $7.85. The total market capitalization recorded 204.87 million. The overall volume in the last trading session was 499,192.00 shares. In its share capital, TG Therapeutics, Inc. (NASDAQ:TGTX) has 27.69 million outstanding shares.
Receptos Inc. (NASDAQ:RCPT) on Mar. 5 provided development program updates and announced financial results for the fourth quarter and year ended December 31, 2013. On Wednesday, shares of Receptos Inc. (NASDAQ:RCPT) advanced 7.12% to close the day at $53.10. Company return on investment (ROI) is 44.50% and its monthly performance is recorded as 20.63%. Receptos Inc. (NASDAQ:RCPT) quarterly revenue growth is 93.72%.